Gilead Sciences is a leader in the field of virology treatments. As VP of clinical research for hepatitis, respiratory and emerging viruses at Gilead, Anu Osinusi talked about the pharma company's work in HIV and hepatitis and how her personal background informed her team's work in developing a Covid-19 treatment.
Bristol-Myers Squibb's move largely impacts its early work in hepatitis B and HIV therapies, though it won't affect the virology therapies currently on the market.
In this episode hear how improving benefit verification, prior authorizations, and patient affordability with smart integrations and real-time eligibility can streamline healthcare workflows.
VP Donnie McGrath said at this week's RESI conference in Houston that Bristol-Myers Squibb is targeting heart failure, virology, immunoscience, rare disease and fibrosis.